A Cost-Effectiveness Analysis of Gefitinib as the First Line Treatment in Patients With Positive Egfr Mutation In Metastatic or Locally Advanced non-Small Cell
Abstract
Authors
T Piha D Barbosa L Fahham
T Piha D Barbosa L Fahham
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now